Tuesday, September 15, 2020 6:22:53 AM
----------------------------
I think I have an Idea that might actually get this board (and the millions of shares it represent) some real influence on future of Amarin - and share value.
----------------------------
Background - is that Retailer's now hold well beyond 50% of shares of Amarin. So us retailers actually from a moral standpoint - have 'just as much say - or even more - than the Tutes at 42%.
https://www.nasdaq.com/market-activity/stocks/amrn/institutional-holdings
a: I know there a number of big individual holdings represented in AMRN
iHub (Raistim. - Downtown - others - I've seen mentioned +200.000
shares).
b: And If everyone (or big majority) we will be able to represent many
millions in share value - in principle even bigger than eg. Baker
Brothers.
----------------------------
The Idea:
Why dont we setup an AMRN Retail investor War Room - that can boil the many great ideas on the board - down to a concrete and precise plan - laid out for retailers to support in an simple vote.
-----------------------------
A group of 10 - max 20 of the ledding minds - on this board (War Room komite) work's out a concrete plan for the ideal way for Amarin to move forward - and thereby rebuild strength and share value for the company.
a: End target for a start is a PDF Presentation document laying out - how
AMRN retailers see as the right way to movw forward - regarding
possible sell (BO) partnership (JV) etc.
b: The document shall at the same time - in a prof. manner (HK + others)
illustrate the enormous potential of Vascepa in CDV and the number of
trials Covid - NASH - Cancer etc.
c: Ideally you will be able to take the final War Room document -
directly to an investment bank - as dokumentation for the potential of
the lifesaving drug of Amarin.
-------------------------------
The first to receive a copy of final document JT and Amarin - with a timeline for a 'real' response.
It is important to see this as a serious attempt to help/assist Amarin growing stronger improving share value - and not as a threat.
On the other hand - if JT and BOD of Amarin would completely ignore 'a collective of retailers' representing big portion of shares of the company - who could blame AMRN War Room - for trying to contact - Investment Banks - Big Pharma trying to convince them of the potential of Amarin - with the right plan in place for the future. As the SP is right now - a god chance that there would be interested.
-------------------------------
I know among others LouieB and others - have been on to the same line of thinking - I just tried to make it a little more concrete.
Jasbg
Recent AMRN News
- Amarin Reports First Quarter 2024 Business Update and Financial Results • GlobeNewswire Inc. • 05/01/2024 11:00:00 AM
- Amarin Applauds HealthyWomen’s Citizen’s Petition Urging FDA To Take Further Action On Fenofibrate Prescribing in Patients at Risk of Cardiovascular Event • GlobeNewswire Inc. • 04/24/2024 06:00:01 PM
- Amarin Announces Results of Annual General Meeting of Shareholders • GlobeNewswire Inc. • 04/22/2024 12:00:25 PM
- Amarin to Report First Quarter 2024 Financial Results and Host Conference Call on May 1, 2024 • GlobeNewswire Inc. • 04/15/2024 12:00:00 PM
- Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24 • GlobeNewswire Inc. • 04/08/2024 12:00:00 PM
- New REDUCE-IT® Analyses Show VASCEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups • PR Newswire (Canada) • 04/08/2024 10:30:00 AM
- New REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups • GlobeNewswire Inc. • 04/06/2024 07:30:00 PM
- Amarin Provides Update on VAZKEPA® (Icosapent Ethyl) Intellectual Property Portfolio in Europe • GlobeNewswire Inc. • 04/03/2024 12:00:00 PM
- Research Evaluating Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the American College of Cardiology’s (ACC) Annual Scientific Session & Expo • GlobeNewswire Inc. • 03/25/2024 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 03/04/2024 10:30:53 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 03/04/2024 01:00:24 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/29/2024 12:06:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/29/2024 12:05:56 PM
- Amarin Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update • GlobeNewswire Inc. • 02/29/2024 12:00:00 PM
- Amarin to Report Fourth Quarter and Full Year 2023 Financial Results and Host Conference on February 29, 2024 • GlobeNewswire Inc. • 02/15/2024 01:00:00 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 02/12/2024 01:00:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 09:31:50 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 09:30:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 09:30:12 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 09:30:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 09:30:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 09:30:11 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/26/2024 12:00:49 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/24/2024 09:31:21 PM
- Amarin Chairman & CEO Issue Letter to Shareholders • GlobeNewswire Inc. • 01/22/2024 12:30:00 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM